$38,398 for a Single Shot of a Very Old Cancer Drug
Why are US hospitals -- which may pay as little as $260 for the drug -- charging so much more to administer it?
Stay updated with breaking news from Ancer Prostate . Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Why are US hospitals -- which may pay as little as $260 for the drug -- charging so much more to administer it?
A shorter course of hypofractionated radiotherapy should be considered for patients with high-risk prostate cancer, say trialists, who report that efficacy and toxicity are similar to longer standard regimens.
177Lu-PSMA SPECT at cycle three (week 12) of six cycles of PSMA-targeted treatment predicted progression-free survival for men with end-stage metastatic castration-resistant prostate cancer.
High PSMA (mean SUV of 10 or greater) predicts good response to 177Lu-PSMA-617 and promises to help clinicians optimize the best patients to treat with the radioligand therapy, researchers say.
Although the findings focus on deaths before vaccines became available, the data can help researchers better understand some of the burden COVID-19 had on patients with cancer.